Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer
18/08/2026 14:05
BRIEF-Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer Oncolytics Biotech Inc ONCY.O:
ONCOLYTICS BIOTECH® ALIGNS WITH FDA ON REGISTRATIONAL PATH FOR SECOND-LINE RAS-MUTANT MSS COLORECTAL CANCER
ONCOLYTICS BIOTECH - RECEIVES FDA FEEDBACK ON PIVOTAL PART B EXPANSION OF REO 033
Source text: ID:nGNX2J99Dk
Further company coverage: ONCY.O
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer
Brief: Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process
Brief: Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer